Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature-Reference-Cited by-同舟云学术

Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature

Published:2021-11-20 Issue: Volume: Page:
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Sriwastava Shitiz^ORCID,Chaudhary Durgesh,Srivastava Samiksha,Beard Katherine,Bai Xue,Wen Sijin,Khalid Syed Hassan,Lisak Robert P.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-021-10910-1.pdf

Reference43 articles.

1. Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H (2017) Benefit-risk profile of Sphingosine-1-Phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs 77(16):1755–1768. https://doi.org/10.1007/s40265-017-0814-1 (PMID: 28905255; PMCID: PMC5661009)

2. Chaudhry BZ, Cohen JA, Conway DS (2017) Sphingosine 1-Phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 14(4):859–873. https://doi.org/10.1007/s13311-017-0565-4 (PMID: 28812220; PMCID: PMC5722770)

3. Subei AM, Cohen JA (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29(7):565–575. https://doi.org/10.1007/s40263-015-0261-z (PMID: 26239599; PMCID: PMC4554772)

4. Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S (2011) Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 2(1):49

5. Al-Salama ZT (2019) Siponimod: first global approval. Drugs 79(9):1009–1015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy;Neurology Clinical Practice;2024-10

2. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy;Neurology Neuroimmunology & Neuroinflammation;2024-09

3. Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report;Journal of Neurology;2024-07-03

4. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-23

5. Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis;ACG Case Reports Journal;2024-04